JPS61171427A - 血栓等予防物質 - Google Patents
血栓等予防物質Info
- Publication number
- JPS61171427A JPS61171427A JP60011679A JP1167985A JPS61171427A JP S61171427 A JPS61171427 A JP S61171427A JP 60011679 A JP60011679 A JP 60011679A JP 1167985 A JP1167985 A JP 1167985A JP S61171427 A JPS61171427 A JP S61171427A
- Authority
- JP
- Japan
- Prior art keywords
- specific
- substance
- reynoutria
- houtt
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000007536 Thrombosis Diseases 0.000 title claims abstract description 16
- 239000000126 substance Substances 0.000 title claims abstract description 16
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 18
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 18
- 241000092659 Pleuropterus Species 0.000 claims abstract description 6
- 244000286023 Polygonum orientale Species 0.000 claims abstract description 5
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 3
- HSTZMXCBWJGKHG-OUUBHVDSSA-N piceide Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-OUUBHVDSSA-N 0.000 claims abstract description 3
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 3
- 229940016667 resveratrol Drugs 0.000 claims abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract 2
- 241000219050 Polygonaceae Species 0.000 claims description 15
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims description 8
- -1 stilbene compound Chemical class 0.000 claims description 8
- 235000021286 stilbenes Nutrition 0.000 claims description 8
- 241000227654 Reynoutria Species 0.000 claims description 5
- 241000632227 Antenoron Species 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 2
- MVLAQMAASMXVFP-GBTPOCJQSA-N (2r,3s,4r,5r)-2-[2,4-dihydroxy-6-[(e)-2-(4-hydroxyphenyl)ethenyl]phenoxy]-3,4,5,6-tetrahydroxyhexanal Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)OC1=C(O)C=C(O)C=C1\C=C\C1=CC=C(O)C=C1 MVLAQMAASMXVFP-GBTPOCJQSA-N 0.000 claims 1
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 abstract description 14
- 241000196324 Embryophyta Species 0.000 abstract description 5
- 241000205426 Persicaria filiformis Species 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 abstract 1
- HSTZMXCBWJGKHG-CENDIDJXSA-N Piceid Natural products OC[C@@H]1O[C@@H](Oc2cc(O)cc(C=Cc3ccc(O)cc3)c2)[C@H](O)[C@H](O)[C@H]1O HSTZMXCBWJGKHG-CENDIDJXSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000003651 drinking water Substances 0.000 abstract 1
- 235000020188 drinking water Nutrition 0.000 abstract 1
- 150000002191 fatty alcohols Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 abstract 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 229940114079 arachidonic acid Drugs 0.000 description 5
- 235000021342 arachidonic acid Nutrition 0.000 description 5
- 238000007395 thrombosis prophylaxis Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000275031 Nica Species 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 240000000691 Houttuynia cordata Species 0.000 description 2
- 235000013719 Houttuynia cordata Nutrition 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- ZNHVWPKMFKADKW-UHFFFAOYSA-N 12-HETE Chemical compound CCCCCC=CCC(O)C=CC=CCC=CCCCC(O)=O ZNHVWPKMFKADKW-UHFFFAOYSA-N 0.000 description 1
- ZNHVWPKMFKADKW-ZYBDYUKJSA-N 12-HETE Natural products CCCCC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-ZYBDYUKJSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KGIJOOYOSFUGPC-CABOLEKPSA-N 5-HETE Natural products CCCCC\C=C/C\C=C/C\C=C/C=C/[C@H](O)CCCC(O)=O KGIJOOYOSFUGPC-CABOLEKPSA-N 0.000 description 1
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 1
- 102000007081 Arachidonate Lipoxygenases Human genes 0.000 description 1
- 108010047815 Arachidonate Lipoxygenases Proteins 0.000 description 1
- 150000008151 D-glucosides Chemical class 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000347881 Kadua laxiflora Species 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000881225 Persicaria Species 0.000 description 1
- 241000688197 Pilosa Species 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60011679A JPS61171427A (ja) | 1985-01-24 | 1985-01-24 | 血栓等予防物質 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60011679A JPS61171427A (ja) | 1985-01-24 | 1985-01-24 | 血栓等予防物質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61171427A true JPS61171427A (ja) | 1986-08-02 |
| JPH0516413B2 JPH0516413B2 (enExample) | 1993-03-04 |
Family
ID=11784678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60011679A Granted JPS61171427A (ja) | 1985-01-24 | 1985-01-24 | 血栓等予防物質 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61171427A (enExample) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994005682A1 (en) * | 1992-08-31 | 1994-03-17 | Francesca Pelizzoni | Combretastatin derivatives with antitumoral activity and process for the preparation thereof |
| WO1999056737A1 (fr) * | 1998-05-05 | 1999-11-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonistes des ligands du recepteur des arylhydrocarbures |
| WO1999059561A3 (en) * | 1998-05-18 | 2000-04-27 | Oklahoma Med Res Found | Resveratrol inhibition of myeloperoxidase |
| WO2000044921A1 (en) * | 1999-01-29 | 2000-08-03 | The Samuel Roberts Noble Foundation, Inc. | Transgenic plants modified to contain resveratrol glucoside and uses thereof |
| JP2002047193A (ja) * | 2000-07-31 | 2002-02-12 | Sunstar Inc | アレルギー性皮膚炎予防または治療用組成物 |
| CN1090603C (zh) * | 1999-09-24 | 2002-09-11 | 四川省凉山州生物研究所 | 一种从中药虎杖中提取白藜芦醇的工艺 |
| US6572882B1 (en) * | 1997-07-15 | 2003-06-03 | Caudalie | Compositions based on resveratrol |
| US6790869B2 (en) | 1999-09-21 | 2004-09-14 | Rutgers, The State University Of New Jersey | Resveratrol analogs for prevention of disease |
| US6974895B1 (en) | 1999-01-29 | 2005-12-13 | The Samuel Roberts Noble Foundation, Inc. | Transgenic legume plants modified to produce resveratrol glucoside and uses thereof |
| AU2003268599B2 (en) * | 1998-05-05 | 2007-03-15 | Casper, Robert Frederic | Arylhydrocarbon Receptor Ligand Antagonists |
| EP1421933A4 (en) * | 2001-07-26 | 2007-09-05 | Inst Radiation Med Amms Pla | USE OF STYLE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF DIABETES AND RETROVIRUS-RELATED DISEASES |
| CN105726508A (zh) * | 2016-01-12 | 2016-07-06 | 中国人民解放军第四军医大学 | 新型二苯乙烯苷缓控释制剂及其制备方法 |
| CN107722079A (zh) * | 2017-10-31 | 2018-02-23 | 桂林纽泰生物科技有限公司 | 从何首乌中提取二苯乙烯苷的方法 |
| CN107903292A (zh) * | 2017-12-26 | 2018-04-13 | 四川文理学院 | 一种何首乌中二苯乙烯苷的提取方法 |
| JP2021501207A (ja) * | 2017-10-27 | 2021-01-14 | 韓國韓醫藥振興院Ｎａｔｉｏｎａｌ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｋｏｒｅａｎ Ｍｅｄｉｃｉｎｅ Ｄｅｖｅｌｏｐｍｅｎｔ | イタドリとシナニッケイとを含む抗血栓用組成物 |
| KR20210014235A (ko) * | 2019-07-29 | 2021-02-09 | 재단법인 경기도경제과학진흥원 | 이삭여뀌 추출물을 이용한 피부 주름 개선 및 피부 미백용 조성물 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2792993A1 (fr) | 2010-01-21 | 2011-07-28 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Composition particuliere pour son application comme medicament |
| FR3068886B1 (fr) | 2017-07-17 | 2019-08-30 | L'oreal | Composition cosmetique aqueuse comprenant un derive d'acide pyridine-dicarboxylique et un hydroxystilbene |
-
1985
- 1985-01-24 JP JP60011679A patent/JPS61171427A/ja active Granted
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994005682A1 (en) * | 1992-08-31 | 1994-03-17 | Francesca Pelizzoni | Combretastatin derivatives with antitumoral activity and process for the preparation thereof |
| US6572882B1 (en) * | 1997-07-15 | 2003-06-03 | Caudalie | Compositions based on resveratrol |
| WO1999056737A1 (fr) * | 1998-05-05 | 1999-11-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonistes des ligands du recepteur des arylhydrocarbures |
| FR2778337A1 (fr) * | 1998-05-05 | 1999-11-12 | Inst Nat Sante Rech Med | Antagonistes des ligands du recepteur des arylhydrocarbures |
| AU2003268599B2 (en) * | 1998-05-05 | 2007-03-15 | Casper, Robert Frederic | Arylhydrocarbon Receptor Ligand Antagonists |
| WO1999059561A3 (en) * | 1998-05-18 | 2000-04-27 | Oklahoma Med Res Found | Resveratrol inhibition of myeloperoxidase |
| WO2000044921A1 (en) * | 1999-01-29 | 2000-08-03 | The Samuel Roberts Noble Foundation, Inc. | Transgenic plants modified to contain resveratrol glucoside and uses thereof |
| US6974895B1 (en) | 1999-01-29 | 2005-12-13 | The Samuel Roberts Noble Foundation, Inc. | Transgenic legume plants modified to produce resveratrol glucoside and uses thereof |
| US6790869B2 (en) | 1999-09-21 | 2004-09-14 | Rutgers, The State University Of New Jersey | Resveratrol analogs for prevention of disease |
| CN1090603C (zh) * | 1999-09-24 | 2002-09-11 | 四川省凉山州生物研究所 | 一种从中药虎杖中提取白藜芦醇的工艺 |
| JP2002047193A (ja) * | 2000-07-31 | 2002-02-12 | Sunstar Inc | アレルギー性皮膚炎予防または治療用組成物 |
| EP1421933A4 (en) * | 2001-07-26 | 2007-09-05 | Inst Radiation Med Amms Pla | USE OF STYLE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF DIABETES AND RETROVIRUS-RELATED DISEASES |
| US7384920B2 (en) | 2001-07-26 | 2008-06-10 | Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla | Use of stilbene compounds in the manufacture of medicament for the prevention and treatment of diabetes or retrovirus-associated diseases |
| CN105726508A (zh) * | 2016-01-12 | 2016-07-06 | 中国人民解放军第四军医大学 | 新型二苯乙烯苷缓控释制剂及其制备方法 |
| JP2021501207A (ja) * | 2017-10-27 | 2021-01-14 | 韓國韓醫藥振興院Ｎａｔｉｏｎａｌ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｋｏｒｅａｎ Ｍｅｄｉｃｉｎｅ Ｄｅｖｅｌｏｐｍｅｎｔ | イタドリとシナニッケイとを含む抗血栓用組成物 |
| CN107722079A (zh) * | 2017-10-31 | 2018-02-23 | 桂林纽泰生物科技有限公司 | 从何首乌中提取二苯乙烯苷的方法 |
| CN107903292A (zh) * | 2017-12-26 | 2018-04-13 | 四川文理学院 | 一种何首乌中二苯乙烯苷的提取方法 |
| KR20210014235A (ko) * | 2019-07-29 | 2021-02-09 | 재단법인 경기도경제과학진흥원 | 이삭여뀌 추출물을 이용한 피부 주름 개선 및 피부 미백용 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0516413B2 (enExample) | 1993-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS61171427A (ja) | 血栓等予防物質 | |
| Akila et al. | Chlorogenic acid ameliorates isoproterenol-induced myocardial injury in rats by stabilizing mitochondrial and lysosomal enzymes | |
| US9694045B2 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases comprising trachelospermi caulis extract and paeonia suffruticosa andrews extract, and method for preparing the same | |
| Ku et al. | Antithrombotic activities of aspalathin and nothofagin via inhibiting platelet aggregation and FIIa/FXa | |
| JP2015515493A5 (enExample) | ||
| JP2008511629A (ja) | 循環器疾患の予防および／または治療のための薬草薬剤組成物ならびにその調製方法 | |
| JPS61161219A (ja) | アトピ−性皮膚炎症用化粧料組成物 | |
| KR20170054882A (ko) | 엉겅퀴 잎 약학적 조성물 | |
| Iman et al. | Preclinical assessment of antiurolithiatic activity of Mangifera indica seeds on ethylene glycol induced urolithiasis rat model | |
| PT1658879E (pt) | Radix salviae miltiorrhizae, o seu extrato e composição para o tratamento de doenças de resistência à aspirina | |
| CN106932508A (zh) | 一种金银花多酚氧化酶复合抑制剂的制备方法及应用 | |
| Irum et al. | Ficus Carica reduces serum uric acid level in Hyperuricemic rats | |
| JP2000191487A (ja) | マトリクスメタロプロテア―ゼ阻害用口腔剤組成物及び飲食品組成物 | |
| Roumili et al. | HPLC analysis, acute toxicity and anti-inflammatory effects of Salix alba L. barks extracts on experimental animal models | |
| KR101536211B1 (ko) | 길경 추출물 또는 이의 분획물을 함유하는 혈전성 질환의 예방 또는 치료용 조성물 | |
| Aruna et al. | FIBRINOLYTIC ACTIVITY OF HIBISCUS ROSA SINENSIS. | |
| KR101671847B1 (ko) | 땃두릅나무 추출물을 유효성분으로 포함하는 혈전 질환의 예방 또는 치료용 조성물 | |
| Takamatsu | Glyoxalase Content in Human Milk and Arakawa's Reaction 106th Report of the Peroxidase Reaction | |
| JPS5939403B2 (ja) | 抗トロンビン様薬剤 | |
| JPS61291525A (ja) | レンギヨウ及び／又はこの近縁種を原料とするアレルギ−及び成人病予防食品 | |
| Christophe et al. | Anti-ulcer and antioxidant activities of the leaf aqueous extract of Corchorus olitorius (Tiliaceae) in rats | |
| Alhazmi | Anticoagulative activity of Commiphora gileadensis, aspirin, and heparin on blood coagulation profiles in naïve mice | |
| KR20180129081A (ko) | 진토닌을 유효성분으로 함유하는 혈전성 질환의 예방 또는 치료용 조성물 | |
| Park et al. | Effects of a Korean herbal formulation, Silsosangami, consisting of seven medicinal herbs, and its seven herbs on endotoxin‐induced experimental thrombosis in rats | |
| KR101972080B1 (ko) | 섬말나리 추출물을 유효성분으로 포함하는 약학적 조성물 |